MiMedx Group, Inc.
MiMedx Group, Inc., a leading biotechnology firm headquartered in the United States, specialises in regenerative medicine and advanced wound care. Founded in 2008, the company has made significant strides in the industry, particularly in the development of placental tissue-based products that promote healing and tissue regeneration.
With a strong presence across North America, MiMedx focuses on innovative solutions for chronic wounds and surgical applications. Its core offerings, including allografts and amniotic tissue products, are distinguished by their unique properties that enhance patient recovery. Recognised for its commitment to quality and efficacy, MiMedx has established a notable market position, contributing to advancements in healthcare and improving patient outcomes.
-14 vs industry average
MiMedx Group, Inc.’s score of 26 is lower than 47% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at MiMedx Group, Inc.?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
Industry performance
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Reported emissions
No reported emissions data is available for MiMedx Group, Inc. yet.
MiMedx Group, Inc.'s reported carbon emissions
MiMedx Group, Inc., headquartered in the US, currently does not report any specific carbon emissions data. However, the company has set ambitious climate commitments aimed at reducing its environmental impact. MiMedx has established a target to reduce its Scope 1 emissions by 25% by 2030, with a baseline starting in 2024. Additionally, the company aims for a similar 25% reduction in its Scope 2 emissions by 2030.
Looking towards the long term, MiMedx has committed to achieving net zero emissions for both Scope 1 and Scope 2 by 2050. These initiatives reflect the company's proactive approach to addressing climate change and its dedication to sustainability within its operations.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
MiMedx Group, Inc.’s Climate Goals (2030 & 2050)
2025
Near-zero scope 1 & 2
Target to achieve near-zero emissions for direct operations and purchased energy
2030
62% reduction in total GHG
Vs 2019 baseline. Validated by SBTi. Includes full supply chain.
2040
50% reduction in Scope 3 intensity
Across purchased goods and services and logistics.
Showing SBTi-validated targets only. Sign up or sign in to see all disclosed climate targets.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Emissions comparison with industry peers
View similar organisations
MiMedx Group, Inc.
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project